Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Excitement starting??

<< Previous

Bullboard Posts

Next >>

Comment by Genie29jon Oct 17, 2022 9:34am

70 Views

Post# 35028628

RE:RE:RE:RE:RE:RE:RE:RE:Excitement starting??

According to my calendar, it hasn't passed. That tweet is about 10 months old... either way, let's hope the news will be positive.

I stand by my original message that they (not any company) would share arbitration info to the public until it's complete. Everyone is assuming the worst at this point, for good reason given replicels track record...but any time AMZN, AAPL, GOOGL, etc are in court/arbitration, they will never share updates, never. I really don't know why people expect Replicel to do anything different

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages